Wellbutrin XL Depression A majority of controlled clinical trials support efficacy of<unk>  for the treatment of depression. However, the overall quality of the evidence is low, with one meta-analysis, for example, finding a small effect size of<unk>  in depression and another finding a large effect size. Comparative head-to-head clinical trials indicate that<unk>  is similar in response rate against depression to fluoxetine, sertraline, paroxetine, and venlafaxine; meanwhile remission rate tends to favor<unk> . Over the fall and winter months,<unk>  prevents development of depression in those who suffer from recurring seasonal affective disorder: 15% of participants on<unk>  experienced a major depressive episode vs. 27% of those on placebo.<unk>  also improves depression in bipolar disorder, with the efficacy and risk of affective switch being similar to other antidepressants.<unk>  has several features that distinguish it from other antidepressants: for instance, unlike the majority of antidepressants, it does not usually cause sexual dysfunction, and the occurrence of sexual side effects is not different from placebo.<unk>  treatment is not associated with weight gain; on the contrary, the majority of studies observed significant weight loss in<unk> -treated participants.<unk>  treatment also is not associated with the sleepiness that may be produced by other antidepressants.<unk>  is more effective than selective serotonin reuptake inhibitors (SSRIs) at improving symptoms of hypersomnia and fatigue in depressed patients. There appears to be a modest advantage for the SSRIs compared to<unk>  in the treatment of depression with high anxiety; they are equivalent for the depression with moderate or low anxiety. The addition of<unk>  to a prescribed SSRI is a common strategy when people do not respond to the SSRI, and it is supported by clinical trials; however, it appears to be inferior to the addition of atypical antipsychotic aripiprazole. Smoking cessation Prescribed as an aid for smoking cessation<unk>  reduces the severity of craving for tobacco and withdrawal symptoms such as depressed mood, irritability, difficulty concentrating, and increased appetite. Initially,<unk>  slows the weight gain that often occurs in the first weeks after quitting smoking. With time, however, this effect becomes negligible. The<unk>  treatment course lasts for seven to twelve weeks, with the patient halting the use of tobacco about ten days into the course. After the course, the effectiveness of<unk>  for maintaining abstinence from smoking declines over time, from 37% of tobacco abstinence at 3 months to 20% at one year. It is unclear whether extending<unk>  treatment helps to prevent relapse of smoking. Overall, six months after the therapy,<unk>  increases the likelihood of quitting smoking by approximately 1.6 fold as compared to placebo. In this respect,<unk>  is as effective as nicotine replacement therapy but inferior to varenicline. Combining<unk>  and nicotine replacement therapy does not improve the quitting rate. In children and adolescents, the use of<unk>  for smoking cessation does not appear to offer any significant benefits. The evidence for its use to aid smoking cessation in pregnant women is insufficient. Attention deficit hyperactivity disorder The treatment of attention deficit hyperactivity disorder (ADHD) is not an approved indication of<unk> , and it is not mentioned in the current (2019) guideline on the ADHD treatment from the American Academy of Pediatrics. Systematic reviews of<unk>  for the treatment of ADHD in both adults and children note that<unk>  may be effective for ADHD but warn that this conclusion has to be interpreted with caution, because clinical trials were of low quality due to small sizes and risk of bias. Similarly to atomoxetine,<unk>  has a delayed onset of action for ADHD, and several weeks of treatment are required for therapeutic effects. This is in contrast to stimulants, such as amphetamine and methylphenidate, which have an immediate onset of effect in the condition. Sexual dysfunction<unk>  is less likely than other antidepressants to cause sexual dysfunction. A range of studies indicate that<unk>  not only produces fewer sexual side effects than other antidepressants but can actually help to alleviate sexual dysfunction including sexual dysfunction induced by SSRI antidepressants. There have also been small studies suggesting that<unk>  or a<unk> /trazodone combination may improve some measures of sexual function in women who have hypoactive sexual desire disorder (HSDD) and are not depressed. According to an expert consensus recommendation from the International Society for the Study of Women's Sexual Health,<unk>  can be considered as an off-label treatment for HSDD despite limited safety and efficacy data. Obesity<unk> , when used for treating obesity over a period of 6 to 12 months, results in an average weight loss of 2.7 kg (5.9 lbs) over placebo. This is not much different from the weight loss produced by several other weight-loss medications such as sibutramine or orlistat. The combination drug naltrexone/bupropion has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of obesity. Other uses<unk>  is not effective in the treatment of cocaine dependence, but it is showing promise in reducing drug use in light methamphetamine users. Based on studies indicating that<unk>  lowers the level of the inflammatory mediator TNF-alpha, there have been suggestions that it might be useful in treating inflammatory bowel disease, psoriasis, and other autoimmune conditions, but very little clinical evidence is available.<unk>  is not effective in treating chronic low back pain. Available forms<unk>  is available as an oral tablet in a number of different formulations. It is formulated mostly as the hydrochloride salt but also to a lesser extent as the hydrobromide salt. The available forms of<unk>  hydrochloride include IR (instant-release) tablets (50, 75, 100 mg), SR (sustained-release) tablets (50, 100, 150, 200 mg), and XL (extended-release) tablets (150, 300, 450 mg). The only marketed form of<unk>  hydrobromide is Aplenzin, an extended-release oral tablet (174, 348, 522 mg). In addition to single-drug formulations,<unk>  is formulated in combinations including naltrexone/bupropion (Contrave; 8 mg/90 mg extended-release tablets) and the pending-approval<unk> /dextromethorphan (AXS-05; 105 mg/45 mg tablets).
Bupropion
Atomoxetine
Hydroxybupropion
Entropion
Citalopram
Duloxetine
Dapoxetine
Fluoxetine